Trial Profile
PREDIX HER2 - Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Docetaxel; Pertuzumab; Trastuzumab
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms PREDIX HER2
- 10 Dec 2022 Results evaluating the prognostic and predictive molecular biomarkers during neoadjuvant HER2-targeting therapy, presented at the 45th Annual San Antonio Breast Cancer Symposium
- 30 Nov 2022 Results assessing the the survival outcomes from PREDIX HER2 and investigate metabolic response and tumor infiltrating lymphocytes (TILs) as prognostic factors during neoadjuvant therapy for HER2-positive breast cancer published in the Clinical Cancer Research
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology